...with its broad range of disease applications, and a team of founding scientists led by LeukoSite Inc....

...treatment, the report concluded. The company has identified small molecule and monoclonal antibody candidate compounds. LeukoSite Inc....

...The companies formed a joint venture to develop Campath-1H , LeukoSite’s monoclonal antibody to treat chronic...
...almost exclusively on lymphocytes. The mechanism destroys malignant cells while sparing the hematopoietic stem cells, LeukoSite...
...depletion was too great for chronic RA therapy. Ilex Oncology Inc. (ILXO), San Antonio, Texas LeukoSite Inc....

...oncology assets. While Millennium had emerged as an oncology play following the 1999 acquisition of LeukoSite Inc....

...When Millennium Pharmaceuticals Inc. landed Velcade bortezomib through its 1999 acquisition of LeukoSite Inc. for $635 million...
...company to another portfolio company, LeukoSite, for $2.3 million in stock and $430,000 in cash. LeukoSite...
...intrigued by the early data associated with the proteasome inhibitor. Three months later, Millennium bought LeukoSite...

...North Carolina Jun 1999 LeukoSite acquires ProScript Oct 1999 Millennium (NASDAQ:MLNM) announces deal to acquire LeukoSite...

...acquired by LeukoSite Inc. (Cambridge, Mass.) for $2.3 million in cash and stock. Later that year, LeukoSite...

...$1,197.8 Aviron (A) $90 $1,500 $1,410 1574% $773.6 Abgenix (ABGX) $88 $1,078 $990 1124% $1,075.7 LeukoSite...

...$61 Geron (GERN) $80 $139 $59 74% $482 DepoMed (DEPO) $34 $58 $25 73% $208 LeukoSite...